Clinical trials: Prediabetic State (IGT)
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT)
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities…
- Conditions
- Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
- Trial name
- NCT02969798
- Testing
- Dapagliflozin, Saxagliptin, Pioglitazone
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes, Impaired Glucose Tolerance
To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients
The aim is to examine whether pharmacological interventions with thiazolidinedione and angiotensin converting enzyme (ACE) inhibitors can reverse pre-clinical vasculopathy in newly diagnosed diabetic and IGT individuals.
- Trial name
- NCT00489229
- Testing
- Rosiglitazone, Ramipril
- Where
- Malaysia
- Volunteers
- 66 people
- Sponsor
- Universiti Sains Malaysia
Healthy, Prediabetic State (IGT)
Noninvasive Transcutaneous Glucometer Development
The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.
- Conditions
- Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT01168076
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Prediabetic State
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels…
- Trial name
- NCT00237250
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Novartis
Prediabetic State (IGT), Prediabetic State
Intestinal Endotoxemia and Beta- Cell Dysfunction in Prediabetics
the goal of this observation study is to learn about association between intestinal endotoxemia and prediabetes lean patients with the aim of prevention of diabetes in those category of patients
- Trial name
- NCT07557329
- Testing
- hba1c, lbp, fasting blood sugar, lipogram, fastinf insulin
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sohag University
Prediabetic State (IGT)
The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of…
- Trial name
- Xuezhikang (NCT06750783)
- Testing
- Xuezhikang, Atorvastatin
- Where
- 3 sites in China
- Volunteers
- 398 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
High Blood Pressure, Metabolic Syndrome
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome.
- Conditions
- High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
- Trial name
- NCT00417170
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Prediabetic State
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e.
- Trial name
- RAPSODI (NCT00325650)
- Testing
- Rimonabant
- Where
- United States
- Volunteers
- 2,420 people
- Sponsor
- Sanofi
Hyperglycemia, Diabetes Mellitus
Lantus in Prediabetes
To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes (IFG or IGT).
- Trial name
- NCT00348972
- Testing
- Lantus® (insulin glargine)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic…
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Trial name
- NCT05067621
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Diabetes Mellitus, Type 2, Atherosclerosis
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
- Trial name
- NCT00995930
- Testing
- ACZ885
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
IGT - Impaired Glucose Tolerance, T2D
Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes
Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion.
- Trial name
- NCT03195400
- Testing
- Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Yale University
Prediabetes, Cardiovascular Risk Factors
A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong
Hypothesis: A high cardiovascular risk is present in subjects with pre-diabetes in Hong Kong Chinese. The investigators plan to assess Chinese subjects in Hong Kong who have pre-diabetes (impaired fasting glucose, IFG; or…
- Trial name
- JADE-HK2 (NCT00786890)
- Testing
- observational, no intervention needed
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Chinese University of Hong Kong
PreDiabetes, Impaired Fasting Glucose (IFG)
Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.
This study evaluates the effect of different doses of metformin on the function of endothelium in people with pre-diabetes. One group of the patients will receive metformin in dose: 1500 mg, the second one will receive 3000…
- Conditions
- PreDiabetes, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT)
- Trial name
- NCT03398356
- Testing
- Metformin
- Where
- Poland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Diabetes, Prediabetes
The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes
Hypothesis : The maximum body weight in lifetime is associated with the onset of development of type 2 diabetes.
- Trial name
- MAXWEL (NCT00816608)
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Bundang Hospital
Diabetes Mellitus, Cancer
Diabetes Prevention Program Outcomes Study
The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired…
- Conditions
- Diabetes Mellitus, Cancer, CVD
- Trial name
- DPPOS (NCT00038727)
- Testing
- DPPOS Group Lifestyle, Metformin, DPPOS Boost Lifestyle
- Where
- United States
- Volunteers
- 2,779 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)